Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: Results of a patient survey

Haemophilia

Volumn 21, Issue 1, 2015, Pages 64-70

  Krishnan, S ^a   Vietri, J ^b   Furlan, R ^b   Duncan, N ^c  

^a BIOGEN   (United States)

^b KANTAR HEALTH   (United States)

^c INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

Adherence; Health related quality of life; Prophylaxis

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CANADA; CHILD; HEALTH SURVEY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SELF REPORT; SHORT FORM 10; SHORT FORM 12; SHORT FORM 6D; SUBSTITUTION THERAPY; UNITED STATES; CLINICAL TRIAL; INFORMATION PROCESSING; MULTICENTER STUDY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

DATA COLLECTION; HEMOPHILIA A; HUMANS; MALE; MEDICATION ADHERENCE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84921609238     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12533     Document Type: Article

References (29)

1. Coppola A, Di Capua M, Di Minno MN et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183-95.
2. Alpkilic Baskirt E, Ak G, Zulfikar B. Oral and general health-related quality of life among young patients with haemophilia. Haemophilia 2009; 15: 193-8.
3. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia A. Bibl Haematol 1970; 34: 111-24.
4. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy-a survey of treatment centres in the United States. Haemophilia 2003; 9: 549-54.
5. Coppola A, Di Capua M, De Simone C. Primary prophylaxis in children with haemophilia. Blood Transfus 2008; 6(Suppl 2): s4-11.
6. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38: 79-94.
7. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88: 329-35.
8. Mondorf W, Kalnins W, Klamroth R. Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy. Haemophilia 2013; 19: 558-63.
9. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
10. Liou WS, Tu TC, Cheng SN et al. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan. Haemophilia 2011; 17: 45-54.
11. Gupta S, Siddiqi AE, Soucie JM et al. The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. Br J Haematol 2013; 161: 424-33.
12. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
13. Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219-27.
14. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
15. Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247-55.
16. Duncan N, Shapiro A, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012; 18: 760-5.
17. McLaughlin JM, Witkop ML, Lambing A, Anderson TL, Munn J, Tortella B. Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophilia. Haemophilia 2014; 20: 506-12.
18. Ware J, Kosinski M, Turner-Bowker D, Gandek B. SF-12v2: How to Score Version 2 of the SF-12 Health Survey. Lincoln, Rhode Island: Quality Metric Incorporated Health Assessment Lab, 2002.
19. Maruish M. User's Manual for the SF-36v2® Health Survey. Lincoln, RI: QualityMetric, incorporated, 2011.
20. Farivar SS, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert Rev Pharmacoecon Outcomes Res 2004; 4: 515-23.
21. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14: 1523-32.
22. Landgraf JM, Abetz L, Ware JE. Child Health Questionnaire (CHQ): A User's Manual. Boston, MA: Health Institute, New England Medical Center, 1996.
23. Fischer K, Collins P, Astermark J et al. Internal and external determinants of bleeding patterns on prophylaxis for severe haemophilia A. Blood 2007; 110: 1145. (Abstract)
24. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adheremce in chronic diseases. Am J Manag Care 2009; 15: e22-33.
25. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-61.
26. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII fusion protein in severe hemophilia A. Blood 123: 317-325.
27. Sleath B, Carpenter DM, Slota C et al. Communication during pediatric asthma visits and self-reported asthma medication adherence. Pediatrics 2012; 130: 627-33.
28. Pappadopulos E, Jensen PS, Chait AR et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 2009; 48: 501-10.
29. Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 2013; 13: 1287-97.